Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics, Inc. (VRDN)
:VRDN
VRDN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.90 - $27.20
Previous CloseN/A
Volume201.32K
Average Volume (3M)990.27K
Market Cap
$1.07B
Enterprise Value$1.03B
Total Cash (Recent Filing)$209.35K
Total Debt (Recent Filing)$697.06K
Price to Earnings (P/E)―
Beta1.73
Next Earnings
May 07, 2025EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.77
Shares Outstanding81,484,950
10 Day Avg. Volume1,377,380
30 Day Avg. Volume990,272
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4117.42
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.41K
Enterprise Value/Ebitda-3.87
Forecast
1Y Price Target
$41.11Price Target Upside213.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Viridian Therapeutics News
PremiumCompany Announcements
Viridian Therapeutics Appoints Jeff Ajer to Board
PremiumCompany Announcements
Viridian Therapeutics Enters New $300M Sale Agreement
PremiumCompany Announcements
Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges
PremiumCompany Announcements
Viridian Therapeutics Reports Strong Progress and Financials
---
Bulls Say, Bears Say
Bulls Say
Earnings PotentialThe target price for VRDN has increased to $48, reflecting positive developments and future potential.
Stock RatingThe analyst recommends an Outperform rating for VRDN, indicating confidence in its future performance.
Bears Say
Development Stage RisksThere is little value ascribed to the FcRn inhibitor franchise at present given the development stage of the programs.
Market PositionThere is little downside risk associated with the VRDN-008 readout given its development stage, while positive data will help draw greater investor attention towards the FcRn.
---
Ownership Overview
4.26% Insiders
26.28% Mutual Funds
0.28% Other Institutional Investors
57.59% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRDN FAQ
What was Viridian Therapeutics, Inc.’s price range in the past 12 months?
Viridian Therapeutics, Inc. lowest stock price was $9.90 and its highest was $27.20 in the past 12 months.
What is Viridian Therapeutics, Inc.’s market cap?
Viridian Therapeutics, Inc.’s market cap is $1.07B.
When is Viridian Therapeutics, Inc.’s upcoming earnings report date?
Viridian Therapeutics, Inc.’s upcoming earnings report date is May 07, 2025 which is in 15 days.
How were Viridian Therapeutics, Inc.’s earnings last quarter?
Viridian Therapeutics, Inc. released its earnings results on Feb 27, 2025. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$1.035 by $0.225.
Is Viridian Therapeutics, Inc. overvalued?
According to Wall Street analysts Viridian Therapeutics, Inc.’s price is currently Undervalued.
Does Viridian Therapeutics, Inc. pay dividends?
Viridian Therapeutics, Inc. does not currently pay dividends.
What is Viridian Therapeutics, Inc.’s EPS estimate?
Viridian Therapeutics, Inc.’s EPS estimate is -0.97.
How many shares outstanding does Viridian Therapeutics, Inc. have?
Viridian Therapeutics, Inc. has 81,484,950 shares outstanding.
What happened to Viridian Therapeutics, Inc.’s price movement after its last earnings report?
Viridian Therapeutics, Inc. reported an EPS of -$0.81 in its last earnings report, beating expectations of -$1.035. Following the earnings report the stock price went down -1.545%.
Which hedge fund is a major shareholder of Viridian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VRDN
---
Viridian Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.11 (213.10% Upside)
$41.11 (213.10% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.06%
12-Months-Change
Fundamentals
Return on Equity
-45.77%
Trailing 12-Months
Asset Growth
51.38%
Trailing 12-Months
Company Description
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
---
VRDN Stock 12 Month Forecast
Average Price Target
$41.11
▲(213.10% Upside)
Technical Analysis
Geron
―
Iovance Biotherapeutics
―
Aurinia Pharmaceuticals
―
Wave Life Sciences
―
Syndax Pharmaceuticals
―
Best Analysts Covering VRDN
1 Year
1 Year Success Rate
15/39 ratings generated profit
1 Year Average Return
-6.72%
reiterated a buy rating 2 months ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -6.72% per trade.
---